Biogen Appoints New CEO
Biogen’s board of directors has appointed Michel Vounatsos as chief executive officer and member of the board of directors, effective January 6, 2017. Vounatsos previously held the position of executive vice president and chief commercial officer at Biogen.
Mr. Vounatsos succeeds George A. Scangos, PhD, who has led the company since 2010 and had previously announced that he would step down once a successor was found. Vounatsos joined Biogen in April 2016 after a 20-year career at Merck & Co. While at Merck, he held leadership positions of increasing responsibility in Europe, China, and the US.
Since joining Biogen, Mr. Vounatsos has demonstrated his global biopharmaceutical experience and track record of stakeholder engagement in his leadership of the company’s commercial organization. He has implemented key initiatives to extend the company’s industry leadership in multiple sclerosis, expanded Biogen’s reach in key global markets, and effectively prepared for the introduction of breakthrough treatments for patients in areas of high unmet need.